RxDoctor Payments Data

Octavio Chavez Herbas, MD

Nephrology · Riverview, FLNPI 1679956163

Payments from drug & device makers

$952in general payments, 2019–2025

Across 43 payments — averaging $22.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vantive US Healthcare LLC$116
  • Novartis$78
  • Boehringer Ingelheim$76
  • Calliditas Therapeutics US Inc.$73
  • Novo Nordisk$68
  • Ardelyx, Inc.$64
  • plus $477 from 13 others

What the payments were for

  • Food & beverage$91896%
  • Education$344%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$952 in reported general payments places this provider in the 35th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$207,429
Medicare patients
414
Services billed
1,739

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JynarqueTolvaptan23$450,342
FarxigaDapagliflozin Propanediol75$74,312
VeltassaPatiromer Calcium Sorbitex44$53,627
Bumetanide253$9,423
Midodrine Hcl26$3,600
Sevelamer Carbonate30$3,380
Calcitriol150$2,753
ProsolParenteral Amino Acid 20% No.126$2,629
Clonidine16$2,549
Potassium Citrate ErPotassium Citrate23$2,400
Hydralazine Hcl86$1,632
Nifedipine ErNifedipine57$1,619
Irbesartan87$1,355
Torsemide83$1,250
Olmesartan Medoxomil94$840

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Jynarque$28$450,34223 claims
AstraZenecaFarxiga$51$74,31275 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 756 nephrology providers in Florida.

Other nephrology in Riverview

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →